NDC 70121-1755

ALYMSYS

Bevacizumab-maly

ALYMSYS is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amneal Pharmaceuticals Llc. The primary component is Bevacizumab.

Product ID70121-1755_726e0e6b-e934-4ac7-92f6-72636a8aec48
NDC70121-1755
Product TypeHuman Prescription Drug
Proprietary NameALYMSYS
Generic NameBevacizumab-maly
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2022-04-15
Marketing CategoryBLA /
Application NumberBLA761231
Labeler NameAmneal Pharmaceuticals LLC
Substance NameBEVACIZUMAB
Active Ingredient Strength400 mg/16mL
Pharm ClassesVascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70121-1755-7

10 CARTON in 1 CARTON (70121-1755-7) > 1 VIAL in 1 CARTON (70121-1755-1) > 16 mL in 1 VIAL
Marketing Start Date2022-04-15
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "ALYMSYS" or generic name "Bevacizumab-maly"

NDCBrand NameGeneric Name
70121-1754ALYMSYSbevacizumab-maly
70121-1755ALYMSYSbevacizumab-maly

Trademark Results [ALYMSYS]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ALYMSYS
ALYMSYS
79304802 not registered Live/Pending
MABXIENCE RESEARCH, S.L.
2021-01-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.